Novartis AG Form 6-K Summary: First Half 2004 Results
Business Context and Reporting Period
This Form 6-K, dated July 20, 2004, reports the unaudited financial results for Novartis AG for the first half (H1) and second quarter (Q2) of 2004. The company, a global leader in pharmaceuticals and consumer health headquartered in Basel, Switzerland, reported strong double-digit growth in sales and income, driven by volume expansion and favorable currency developments.
Key Financial Metrics
| Metric | H1 2004 (USD m) | H1 2003 (USD m) | % Change | Q2 2004 (USD m) | Q2 2003 (USD m) | % Change |
|---|---|---|---|---|---|---|
| Total Sales | 13,612 | 11,924 | 14% | 6,973 | 6,203 | 12% |
| Pharmaceutical Sales | 8,882 | 7,600 | 17% | 4,572 | 3,991 | 15% |
| Consumer Health Sales | 4,730 | 4,324 | 9% | 2,401 | 2,212 | 9% |
| Operating Income | 3,288 | 2,814 | 17% | 1,794 | 1,463 | 23% |
| Operating Margin | 24.2% | 23.6% | +0.6 pp | 25.7% | 23.6% | +2.1 pp |
| Net Income | 2,842 | 2,379 | 19% | 1,549 | 1,316 | 18% |
| Basic EPS (USD) | 1.16 | 0.96 | 21% | 0.63 | 0.53 | 19% |
| Free Cash Flow (H1) | 347 | 657 | -310 | - | - | - |
| Net Liquidity | 6,313 | 4,167 | +2,146 | - | - | - |
Note: Free cash flow after dividend payments fell by USD 310 million in H1 2004, primarily due to increased dividend payments. Net liquidity increased to USD 6.3 billion.
Material Changes vs. Prior Period
- Sales Growth Drivers: Group sales grew 14% (9% in local currencies). Volume expansion contributed 7 percentage points, currency benefits added 5 percentage points, while acquisitions and price increases each added 1 percentage point.
- Pharmaceuticals: Sales rose 17% (11% lc), driven by primary care brands (Diovan, Lotrel, Lamisil, Trileptal) and specialty medicines (Gleevec, Zometa, Femara, Visudyne). Specialty medicines now account for 33% of Pharma sales.
- Consumer Health: Sales increased 9% (4% lc). OTC, Medical Nutrition, and CIBA Vision posted double-digit USD growth. Sandoz (Generics) sales were flat (0% USD, -6% lc) due to US declines offset by growth in France and Spain.
- Profitability: Operating income grew faster than sales (17% vs 14%) due to margin expansion. Gross profit margin improved to 77.0%. R&D costs as a percentage of sales declined to 14% from 15%.
- One-Time Items: Other income/expenses included a USD 292 million charge in H1 2004, compared to a USD 70 million charge in H1 2003. The prior year included a USD 178 million gain from the Fioricet/Fiorinal divestment.
Guidance, Outlook, and Risks
Outlook: Management expects strong business expansion to continue. For the full year 2004, Novartis forecasts high-single-digit sales growth in local currencies for the Group and high-single-digit to low-double-digit growth for Pharmaceuticals. The company anticipates markedly higher operating and net income for the full year.
Pipeline Highlights: Key projects are on schedule. Notable developments include:
- Femara: FDA granted priority review for extended adjuvant breast cancer indication; data showed 40% reduction in recurrence risk.
- Gleevec: Continued growth in CML and GIST; patient assistance programs expanded to 67 countries.
- Enablex: QTc study confirmed safety profile; submitted to FDA.
- Zoledronic Acid: Submitted in EU for Paget's disease; US submission expected Q4 2004.
Risks and Contingencies: Forward-looking statements are subject to risks including regulatory delays, clinical trial results, patent protection, and government pricing pressures. The filing notes that actual results may vary materially from expectations.
Investor Verification Checklist
- Currency Impact: Verify the sustainability of sales growth excluding the 5 percentage point currency benefit.
- Sandoz Performance: Monitor the impact of generic competition on Sandoz, particularly in the US market where sales declined 19%.
- R&D Investment: Confirm the acceleration of R&D spending in the second half of 2004 as indicated by management.
- Regulatory Approvals: Track upcoming decisions for Enablex, Zelnorm, Certican, and the expanded Femara indication.
- Free Cash Flow: Assess the impact of increased dividend payments and share repurchases (USD 869 million in H1) on liquidity.